SG11202008230PA - Compounds with ferroptosis inducing activity and methods of their use - Google Patents
Compounds with ferroptosis inducing activity and methods of their useInfo
- Publication number
- SG11202008230PA SG11202008230PA SG11202008230PA SG11202008230PA SG11202008230PA SG 11202008230P A SG11202008230P A SG 11202008230PA SG 11202008230P A SG11202008230P A SG 11202008230PA SG 11202008230P A SG11202008230P A SG 11202008230PA SG 11202008230P A SG11202008230P A SG 11202008230PA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- methods
- inducing activity
- ferroptosis
- ferroptosis inducing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000004806 ferroptosis Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862636614P | 2018-02-28 | 2018-02-28 | |
| PCT/US2019/019854 WO2019168999A1 (en) | 2018-02-28 | 2019-02-27 | Compounds with ferroptosis inducing activity and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202008230PA true SG11202008230PA (en) | 2020-09-29 |
Family
ID=65729467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202008230PA SG11202008230PA (en) | 2018-02-28 | 2019-02-27 | Compounds with ferroptosis inducing activity and methods of their use |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11098040B2 (en) |
| EP (1) | EP3759075B1 (en) |
| JP (1) | JP7348906B2 (en) |
| KR (1) | KR20200135961A (en) |
| CN (1) | CN112041301A (en) |
| AR (2) | AR114417A1 (en) |
| AU (1) | AU2019229256A1 (en) |
| BR (1) | BR112020017561A2 (en) |
| CA (1) | CA3092143A1 (en) |
| EA (1) | EA202091846A1 (en) |
| IL (1) | IL276788A (en) |
| MX (2) | MX2020008906A (en) |
| SG (1) | SG11202008230PA (en) |
| TW (1) | TW202000663A (en) |
| WO (1) | WO2019168999A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220012221A (en) * | 2019-02-27 | 2022-02-03 | 페로 테라퓨틱스 인코포레이티드 | Compounds having peroptosis inducing activity and methods of using the same |
| US11040964B2 (en) | 2019-02-27 | 2021-06-22 | Ferro Therapeutics, Inc. | Compounds and methods of use |
| WO2021041539A2 (en) * | 2019-08-28 | 2021-03-04 | Ferro Therapeutics, Inc. | Compounds and methods of use |
| CN110511253B (en) * | 2019-09-04 | 2023-10-13 | 上海药明康德新药开发有限公司 | Synthesis method of On-DNA tetrahydro-beta-carboline compound in construction of DNA coding compound library |
| CN110627786B (en) * | 2019-10-29 | 2020-11-24 | 株洲千金药业股份有限公司 | Preparation method of tadalafil intermediate |
| JP2023509359A (en) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | Combination anticancer therapy with inducers of iron-dependent cell degradation |
| US11998534B2 (en) * | 2020-02-12 | 2024-06-04 | Eubulus Biotherapeutics Inc. | GPX4 inhibitor in combination with anticancer agent for treating proliferative disease |
| JP2023518132A (en) * | 2020-03-06 | 2023-04-27 | ベイジン・シノタウ・バイオ－ファーマシューティカルズ・テクノロジー・カンパニー，リミテッド | Application of CTB006 in combination with ponatinib |
| US20240092739A1 (en) * | 2020-08-26 | 2024-03-21 | Ferro Therapeutics, Inc | Compounds and methods of use |
| CN118076602A (en) * | 2020-12-04 | 2024-05-24 | 嘉兴优博生物技术有限公司 | Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses |
| KR20220139813A (en) * | 2021-04-08 | 2022-10-17 | 서울대학교산학협력단 | A biomarker for predicting prognosis in patients with cancer and use thereof |
| CN113336748B (en) * | 2021-04-12 | 2022-03-25 | 北京大学 | GPX4 protein degradation agent, preparation method and application thereof, and anti-tumor cell drug |
| US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
| WO2024015637A1 (en) * | 2022-07-15 | 2024-01-18 | Ferro Therapeutics, Inc. | Glutathione peroxidase 4 (gpx4) inhibitors for the treatment of cancer |
| AU2023324856A1 (en) * | 2022-08-19 | 2025-01-30 | Olema Pharmaceuticals, Inc. | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer |
| WO2024123412A1 (en) * | 2022-12-09 | 2024-06-13 | The University Of Toledo | Ferroptosis inducers to treat cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9514465D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| JP2004501124A (en) * | 2000-06-07 | 2004-01-15 | リリー アイコス リミテッド ライアビリティ カンパニー | Compound |
| US20030153575A1 (en) * | 2000-06-08 | 2003-08-14 | Orme Mark W. | Tetracyclic diketopiperazine compounds as pdev inhibitors |
| MXPA03002914A (en) * | 2000-10-02 | 2003-09-10 | Lilly Icos Llc | Hexahydropyrazino `1 2 : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction. |
| CA2427608C (en) | 2000-11-08 | 2010-05-04 | Lilly Icos Llc | Condensed pyradizindione derivatives as pde inhibitors |
| WO2007016361A2 (en) * | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
| EP1914235A1 (en) | 2006-10-10 | 2008-04-23 | Universite de Lille 2 Droit et Santé | Chiral tetra-hydro beta-carboline derivatives and applications thereof as antiparasitic compounds |
| WO2008103470A2 (en) | 2007-02-21 | 2008-08-28 | Trustees Of Columbia University In The City Of New York | Oncogenic-ras-signal dependent lethal compounds |
| FR2916200A1 (en) * | 2007-05-18 | 2008-11-21 | Fourtillan Snc | New 1,2,3,4,6,7,12,12a-octahydro-pyrazino(1',2':1,6)pyrido(3,4-b)indole compounds are 5-hydroxy tryptamine-2 receptor antagonist useful to treat e.g. depression, anxiety, Parkinson's disease, Alzheimer's disease and cancer |
| US9169247B2 (en) | 2009-11-20 | 2015-10-27 | Southern Research Institute | Tetrahydro-beta-carboline derivatives, synthesis and use thereof |
| US9695133B2 (en) * | 2012-07-13 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use |
| WO2015051149A1 (en) | 2013-10-04 | 2015-04-09 | The Trustees Of Columbia University In The City Of New York | Sorafenib analogs and uses thereof |
| EP3094332B1 (en) | 2014-01-15 | 2018-09-12 | The Trustees of Columbia University in the City of New York | Carbonyl erastin analogs and their use |
| CN107530303A (en) | 2014-12-16 | 2018-01-02 | Adt制药有限责任公司 | RAS inhibition indenyls acetamide compound, composition and purposes |
| WO2016196201A1 (en) | 2015-05-29 | 2016-12-08 | Memorial Sloan Kettering Cancer Center | Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis |
| EP3378861B1 (en) | 2015-11-12 | 2021-08-04 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| WO2017120445A1 (en) * | 2016-01-07 | 2017-07-13 | The Broad Institute, Inc. | Compounds and methods for increasing tumor infiltration by immune cells |
| BR112018013730B1 (en) | 2016-01-08 | 2022-06-28 | Championx Usa Inc. | METHOD TO INTENSE PRODUCTION AND/OR TRANSPORT OF CRUDE OIL |
| MX387596B (en) | 2016-02-05 | 2025-03-18 | Inventisbio Llc | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND THEIR USES. |
| WO2018118711A1 (en) | 2016-12-19 | 2018-06-28 | The Trustees Of Columbia University In The City Of New York | Small molecule ferroptosis inducers |
| US20200138829A1 (en) | 2017-05-24 | 2020-05-07 | Ferro Therapeutics, Inc. | Methods of cancer treatment |
| EP4085919A3 (en) | 2017-07-21 | 2023-02-08 | Novartis AG | Compositions and methods to treat cancer |
| WO2019106434A1 (en) | 2017-12-01 | 2019-06-06 | Collaborative Medicinal Development Pty. Ltd. | Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders |
| US20200383943A1 (en) | 2017-12-04 | 2020-12-10 | Memorial Sloan Kettering Cancer Center | Methods of cancer treatment via regulated ferroptosis |
| CN109796424A (en) | 2019-02-19 | 2019-05-24 | 四川大学 | A kind of small molecule compound and the preparation method and application thereof inhibiting iron death |
| KR20220012221A (en) | 2019-02-27 | 2022-02-03 | 페로 테라퓨틱스 인코포레이티드 | Compounds having peroptosis inducing activity and methods of using the same |
-
2019
- 2019-02-27 EP EP19710558.8A patent/EP3759075B1/en active Active
- 2019-02-27 CA CA3092143A patent/CA3092143A1/en active Pending
- 2019-02-27 EA EA202091846A patent/EA202091846A1/en unknown
- 2019-02-27 JP JP2020545666A patent/JP7348906B2/en active Active
- 2019-02-27 CN CN201980028824.0A patent/CN112041301A/en active Pending
- 2019-02-27 US US16/287,805 patent/US11098040B2/en active Active
- 2019-02-27 TW TW108106912A patent/TW202000663A/en unknown
- 2019-02-27 AU AU2019229256A patent/AU2019229256A1/en not_active Abandoned
- 2019-02-27 SG SG11202008230PA patent/SG11202008230PA/en unknown
- 2019-02-27 BR BR112020017561-7A patent/BR112020017561A2/en not_active IP Right Cessation
- 2019-02-27 MX MX2020008906A patent/MX2020008906A/en unknown
- 2019-02-27 KR KR1020207027582A patent/KR20200135961A/en not_active Withdrawn
- 2019-02-27 WO PCT/US2019/019854 patent/WO2019168999A1/en unknown
- 2019-02-28 AR ARP190100499A patent/AR114417A1/en not_active Application Discontinuation
-
2020
- 2020-02-27 AR ARP200100540A patent/AR118205A1/en not_active Application Discontinuation
- 2020-08-18 IL IL276788A patent/IL276788A/en unknown
- 2020-08-26 MX MX2023001527A patent/MX2023001527A/en unknown
-
2021
- 2021-07-06 US US17/368,708 patent/US20230039846A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190263802A1 (en) | 2019-08-29 |
| JP7348906B2 (en) | 2023-09-21 |
| JP2021515010A (en) | 2021-06-17 |
| AR118205A1 (en) | 2021-09-22 |
| KR20200135961A (en) | 2020-12-04 |
| MX2023001527A (en) | 2023-03-06 |
| EP3759075A1 (en) | 2021-01-06 |
| EA202091846A1 (en) | 2021-06-01 |
| AU2019229256A1 (en) | 2020-09-17 |
| MX2020008906A (en) | 2021-02-26 |
| WO2019168999A1 (en) | 2019-09-06 |
| IL276788A (en) | 2020-10-29 |
| AR114417A1 (en) | 2020-09-02 |
| CN112041301A (en) | 2020-12-04 |
| US20230039846A1 (en) | 2023-02-09 |
| BR112020017561A2 (en) | 2020-12-22 |
| EP3759075B1 (en) | 2025-07-23 |
| TW202000663A (en) | 2020-01-01 |
| CA3092143A1 (en) | 2019-09-06 |
| US11098040B2 (en) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276788A (en) | Compounds with ferroptosis inducing activity and methods of their use | |
| IL290809B1 (en) | Tau-protein targeting protacs and associated methods of use | |
| IL285730A (en) | Compounds with ferroptosis inducing activity and methods of their use | |
| IL273918A (en) | Trispecific proteins and methods of use | |
| EP3946690A4 (en) | PERFLUORICYL AND POLYFLUORICYL SORPENTANTS AND METHODS OF USE | |
| ZA201905677B (en) | Glycan-interacting compounds and methods of use | |
| HUE068842T2 (en) | Compounds and their methods of use | |
| IL292810A (en) | Therapeutic compounds and methods of use | |
| IL289748A (en) | Heterodimers and methods of use thereof | |
| IL283782A (en) | Anellosomes and methods of use | |
| IL276687A (en) | Trialkyne linking agents and methods of use | |
| IL320977A (en) | Auto-injector and related methods of use | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| IL277963A (en) | Bicyclic carboxamides and methods of use thereof | |
| IL265955A (en) | Therapeutic compounds and methods of use thereof | |
| IL255565A (en) | Substituted benzamides and methods of use thereof | |
| ZA202005674B (en) | Glucoamylases and methods of use thereof | |
| GB201813312D0 (en) | Compounds and their therapeutic use | |
| IL276053A (en) | Therapeutic-gard and method of use thereof | |
| ZA201908276B (en) | Charge-tagged nucleotides and methods of use thereof | |
| ZA201802134B (en) | Therapeutic compounds and methods of use thereof | |
| GB201900741D0 (en) | Liver-specifc inducible prometers and methods of use thereof | |
| GB2589398B (en) | Compounds and methods of use | |
| IL276792A (en) | Inhaler and methods of use thereof | |
| HK40044860A (en) | Compounds with ferroptosis inducing activity and methods of their use |